{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:22:57Z","timestamp":1794576177057,"version":"4.9.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101194710"],"award-info":[{"award-number":["101194710"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jcyt.2026.102939","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:32:04Z","timestamp":1781911924000},"page":"102939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3838-6576","authenticated-orcid":false,"given":"Dominik","family":"Griebling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rebecca","family":"Scheiwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Kuhlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Zech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rische","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5669-4502","authenticated-orcid":false,"given":"Vivian","family":"L\u00e4ngst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Bothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-5055","authenticated-orcid":false,"given":"Katrin","family":"Mestermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Sanges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Krones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"D\u00fcnkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hudecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-9160","authenticated-orcid":false,"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-6202","authenticated-orcid":false,"given":"Ayal","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Kashanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-7343","authenticated-orcid":false,"given":"Julia","family":"Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7554-6062","authenticated-orcid":false,"given":"Tuula","family":"Rintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-8344","authenticated-orcid":false,"given":"Afschin","family":"Gandjour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa D.","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-4843","authenticated-orcid":false,"given":"Patrick","family":"Mennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-8152","authenticated-orcid":false,"given":"Eduard Christiaan","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Vosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-666X","authenticated-orcid":false,"given":"Julia","family":"Busch-Casler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-2065","authenticated-orcid":false,"given":"Marija","family":"Radic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-8673","authenticated-orcid":false,"given":"Ralf","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brzoska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9314-0759","authenticated-orcid":false,"given":"Catrina","family":"Pietralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-4795","authenticated-orcid":false,"given":"Jens O.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6882-8603","authenticated-orcid":false,"given":"Theresa","family":"Kagerbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Z\u00fcndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S.","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-8027","authenticated-orcid":false,"given":"Nattaporn","family":"Phanthaphol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan R.","family":"Rodriguez Madoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-7628","authenticated-orcid":false,"given":"Cristina","family":"Carames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Steppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102939_bib0001","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2026.102939_bib0002","unstructured":"IQVIA Institute for Human Data Science. Achieving CAR T-cell Therapy Health System Readiness: An Assessment of Barriers and Opportunities. 2025. Available from: https:\/\/www.iqviainstitute.org."},{"key":"10.1016\/j.jcyt.2026.102939_bib0082","unstructured":"Business Wire. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster [Internet]. San Francisco (CA): Business Wire; 2024 Apr 22 [cited 2026 Jul 7]. Available from: https:\/\/www.businesswire.com\/news\/home\/20240422361723\/en\/Bristol-Myers-Squibb-and-Cellares-Announce-a-380M-Worldwide-Capacity-Reservation-and-Supply-Agreement-for-the-Manufacture-of-CAR-T-Cell-Therapies-to-Bring-the-Promise-of-Cell-Therapy-to-More-Patients-Faster"},{"key":"10.1016\/j.jcyt.2026.102939_bib0057","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of response to B-cell maturation antigen-directed mrna cell therapy in myasthenia gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0083","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood-2021-154013","article-title":"Eight-day point of care CAR T-cell manufacturing on clinimacs prodigy from healthy donors as a proof-of-concept study","volume":"138","author":"Hankey","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0084","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0085","doi-asserted-by":"crossref","first-page":"10323","DOI":"10.1182\/blood-2022-163830","article-title":"Initial clinical results of Atalanta-1, a phase I\/II trial of point-of-care manufactured GLPG5102 (19CP02) in RR NHL","volume":"140","author":"Anguille","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0086","unstructured":"ARCE Therapeutics. DashCAR\u00ae [Internet]. Taipei (Taiwan): ARCE Therapeutics; date unknown [cited 2026 Jul 7]. Available from: https:\/\/www.arcetherapeutics.com\/research\/dash_car"},{"key":"10.1016\/j.jcyt.2026.102939_bib0087","unstructured":"Gracell Biotechnologies. FasTCAR: our next-day manufacturing autologous platform [Internet]. Shanghai (China): Gracell Biotechnologies; 2024 Oct [cited 2026 Jul 7]. Available from: https:\/\/www.gracellbio.com\/fastcar\/"},{"key":"10.1016\/j.jcyt.2026.102939_bib0088","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jcyt.2024.03.016","article-title":"Development of ingenui-T, a rapid autologous chimeric antigen receptor (CAR)-T manufacturing solution using whole blood, for treatment of autoimmune disease","volume":"26","author":"Anaya","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102939_bib0089","unstructured":"Kyverna Therapeutics. CAR T-cell therapy for autoimmune diseases [Internet]. Emeryville (CA): Kyverna Therapeutics; date unknown [cited 2026 Jul 7]. Available from: https:\/\/kyvernatx.com\/platform-pipeline\/car-t-cell-therapy\/"},{"key":"10.1016\/j.jcyt.2026.102939_bib0090","article-title":"Full speed ahead: how rapid CAR-T manufacturing can shape the cell therapy landscape","author":"Henckels","year":"2025","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.jcyt.2026.102939_bib0030","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-cell maturation antigen (BCMA) NEX-T\u00ae chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102939_bib0091","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood-2021-146268","article-title":"A first-in-human study of YTB323, a novel, autologous CD19-directed CAR-T cell therapy manufactured using the novel T-Charge TM platform, for the treatment of patients (Pts) with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL)","volume":"138","author":"Flinn","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0092","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2021-146246","article-title":"Preservation of T-Cell stemness with a novel expansionless CAR-T manufacturing process, which reduces manufacturing time to less than two days, drives enhanced CAR-T cell efficacy","volume":"138","author":"Engels","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0093","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2021-148390","article-title":"Identification and development of PHE885: a novel and highly potent fully human anti-BCMA CAR-T manufactured with a novel T-charge TM platform for the treatment of multiple myeloma","volume":"138","author":"Bu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0094","unstructured":"Galapagos NV. Galapagos announces intention to wind down cell therapy business as part of the company\u2019s ongoing transformation [press release]. Mechelen (Belgium): Galapagos NV; 2025 Oct 21 [cited 2026 Jul 7]. Available from: https:\/\/lakefrontbio.com\/press-releases\/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation\/"},{"key":"10.1016\/j.jcyt.2026.102939_bib0003","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1080\/14796694.2024.2393566","article-title":"Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals","volume":"20","author":"Sureda","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0004","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102939_bib0005","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2022-158327","article-title":"Ethical Prioritization of Patients to CAR T-Cell Therapies: Tool Development and Process","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0006","article-title":"Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries","volume":"10","author":"Canales Albendea","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jcyt.2026.102939_bib0007","unstructured":"European Commission Directorate-General for Health and Food Safety; European Medicines Agency. Action Plan on ATMPs [Internet]. 2017 Oct 20 [cited 2026 Jul 6]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-commission-dg-health-and-food-safety-and-european-medicines-agency-action-plan-advanced-therapy-medicinal-products-atmps_en.pdf"},{"issue":"6372","key":"10.1016\/j.jcyt.2026.102939_bib0008","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102939_bib0009","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102939_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","article-title":"Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study","volume":"12","author":"Yang","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102939_bib0011","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/bloodadvances.2023012240","article-title":"Don't keep me waiting\u201d: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes","volume":"8","author":"Vadgama","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102939_bib0012","doi-asserted-by":"crossref","first-page":"1238535","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"key":"10.1016\/j.jcyt.2026.102939_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114361","article-title":"Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India","volume":"201","author":"S S","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jcyt.2026.102939_bib0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jval.2022.12.014","article-title":"Financing and Reimbursement of Approved Advanced Therapies in Several European Countries","volume":"26","author":"Iglesias-L\u00f3pez","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jcyt.2026.102939_bib0015","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1016\/j.jval.2023.09.1801","article-title":"HTA117 A Comparison of Health Technology Appraisal (HTA) Timelines and Requirements for Orphan Technologies in 10 European Countries","volume":"26","author":"Mumford","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jcyt.2026.102939_bib0016","unstructured":"Clinical Study Unit (CSU), European Society for Blood and Marrow Transplantation. CAR-T Data Collection Initiative: Supporting Post-Authorization Studies (PAS) to monitor the long-term safety and\/or effectiveness of CAR T-cell therapies [poster]. 51st Annual Meeting of the EBMT; 2025 Mar 30; Florence, Italy. Available from: https:\/\/www.ebmt.org\/sites\/default\/files\/2025-03\/EBMT%202025%20Annual%20Meeting%20Poster_DCI.pdf"},{"key":"10.1016\/j.jcyt.2026.102939_bib0017","article-title":"Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies","volume":"37","author":"Chabannon","year":"2024","journal-title":"Best Pr Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0018","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102939_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.057","article-title":"Automated manufacturing of cell therapies","volume":"381","author":"Melocchi","year":"2025","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102939_bib0020","doi-asserted-by":"crossref","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102939_bib0021","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcyt.2025.05.006","article-title":"A 3-in-1 integrated automated platform for rapid CAR-T cell manufacturing: activation, transduction, and expansion in a hollow-fiber system","volume":"27","author":"Wang","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102939_bib0022","unstructured":"Cellares. Services [Internet]. South San Francisco (CA): Cellares; 2025 [cited 2026 Jul 7]. Available from: https:\/\/www.cellares.com\/services\/"},{"key":"10.1016\/j.jcyt.2026.102939_bib0023","unstructured":"Ori Biotech. Scale your impact: introducing IRO, the new standard in CGT manufacturing technology [Internet]. Philadelphia (PA): Ori Biotech; 2025 [cited 2026 Jul 7]. Available from: https:\/\/oribiotech.com\/IRO"},{"key":"10.1016\/j.jcyt.2026.102939_bib0024","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102939_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR T cells","volume":"10","author":"Lock","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102939_bib0026","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1182\/bloodadvances.2025016181","article-title":"Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed\/refractory or in very-high-risk first relapse","volume":"9","author":"Del Bufalo","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102939_bib0027","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","article-title":"A novel autologous CAR-T Therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development","volume":"13","author":"Dickinson","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2026.102939_bib0028","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2026.102939_bib0029","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jcyt.2026.102939_bib0031","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1182\/blood-2022-155603","article-title":"Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r\/r) large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0032","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3389\/fimmu.2019.02361","article-title":"GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy","volume":"10","author":"Fern\u00e1ndez","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102939_bib0033","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/app14031303","article-title":"Integrating artificial intelligence for academic advanced therapy medicinal products: challenges and opportunities","volume":"14","author":"Aguilar-Gallardo","year":"2024","journal-title":"Appl Sci"},{"key":"10.1016\/j.jcyt.2026.102939_bib0034","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"191","article-title":"The Regulatory framework for CAR-T cells in Europe: current status and foreseeable changes and centre qualification by competent authorities and manufacturers","author":"McGrath","year":"2022"},{"key":"10.1016\/j.jcyt.2026.102939_bib0035","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/07036337.2012.711825","article-title":"Common market but divergent regulatory practices: exploring European regulation and the effect on regulatory uncertainty in the marketing authorization of medical products","volume":"35","author":"Chowdhury","year":"2013","journal-title":"J Eur Integr"},{"key":"10.1016\/j.jcyt.2026.102939_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70243","article-title":"Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee","volume":"9","author":"van Sinderen","year":"2025","journal-title":"Hemasphere"},{"key":"10.1016\/j.jcyt.2026.102939_bib0037","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0038","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102939_bib0039","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102939_bib0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s10147-023-02319-9","article-title":"piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies","volume":"28","author":"Yagyu","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0041","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0042","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma","volume":"28","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102939_bib0043","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/bies.201000027","article-title":"Translating Sleeping Beauty transposition into cellular therapies: victories and challenges","volume":"32","author":"Izsv\u00e1k","year":"2010","journal-title":"Bioessays"},{"key":"10.1016\/j.jcyt.2026.102939_bib0044","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102939_bib0045","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.ymthe.2021.08.013","article-title":"Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy","volume":"29","author":"Schambach","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102939_bib0046","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jcyt.2026.102939_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030965","article-title":"Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation","volume":"26","author":"Kitte","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2026.102939_bib0048","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102939_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"issue":"6753","key":"10.1016\/j.jcyt.2026.102939_bib0050","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102939_bib0051","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0052","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102939_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102939_bib0054","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jcyt.2026.102939_bib0055","doi-asserted-by":"crossref","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102939_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102939_bib0058","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT06917742, A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE); 2025 [updated 2026 Apr 1; cited 2026 Jul 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06917742"},{"key":"10.1016\/j.jcyt.2026.102939_bib0059","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT06694298, A Phase I Clinical Study of BCMA Chimeric Antigen Receptor T Cell (SYS6020) Injection in Refractory Active Systemic Lupus Erythematosus Patients; 2024 Nov 19 [cited 2026 Jul 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06694298"},{"key":"10.1016\/j.jcyt.2026.102939_bib0060","unstructured":"European Commission. T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy (grant agreement ID: 945393) [Internet]. Brussels (Belgium): European Commission; 2021 [cited 2026 Jul 7]. doi:10.3030\/945393. Available from: https:\/\/cordis.europa.eu\/project\/id\/945393"},{"key":"10.1016\/j.jcyt.2026.102939_bib0061","unstructured":"European Society for Blood and Marrow Transplantation. GoCART Coalition [Internet]. Barcelona (Spain): EBMT; 2021 [cited 2026 Jul 7]. Available from: https:\/\/www.ebmt.org\/research\/gocart-coalition"},{"key":"10.1016\/j.jcyt.2026.102939_bib0062","unstructured":"European Commission. AIDPATH: Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital (grant agreement ID: 101016909) [Internet]. Brussels (Belgium): European Commission; 2021 [cited 2026 Jul 7]. doi:10.3030\/101016909. Available from: https:\/\/cordis.europa.eu\/project\/id\/101016909"},{"key":"10.1016\/j.jcyt.2026.102939_bib0063","unstructured":"European Commission. JOIN4ATMP: Map, join and drive European activities for advanced therapy medicinal product development and implementation for patient and society benefit (grant agreement ID: 101137206) [Internet]. Brussels (Belgium): European Commission; 2024 [cited 2026 Jul 7]. doi:10.3030\/101137206. Available from: https:\/\/cordis.europa.eu\/project\/id\/101137206"},{"key":"10.1016\/j.jcyt.2026.102939_bib0064","unstructured":"European Commission. EASYGEN: EASY workflow integration for GENe therapy (grant agreement ID: 101194710) [Internet]. Brussels (Belgium): European Commission; 2025 [cited 2026 Jul 7]. doi:10.3030\/101194710. Available from: https:\/\/cordis.europa.eu\/project\/id\/101194710"},{"key":"10.1016\/j.jcyt.2026.102939_bib0065","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1038\/s41598-022-10320-x","article-title":"Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation","volume":"12","author":"Radisch","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102939_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1328368","article-title":"Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III\/IV melanoma","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0067","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","article-title":"Expanding access to CAR T cell therapies through local manufacturing","volume":"41","author":"Elsallab","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0068","series-title":"Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 1394\/2007","first-page":"17","year":"2007"},{"key":"10.1016\/j.jcyt.2026.102939_bib0069","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jcyt.2022.03.007","article-title":"Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products","volume":"24","author":"Cuende","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102939_bib0070","article-title":"Harnessing digital health technologies and real-world evidence to enhance clinical research and patient outcomes","volume":"11","author":"Mahadik","year":"2025","journal-title":"DIGIT HEALTH"},{"key":"10.1016\/j.jcyt.2026.102939_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101557","article-title":"Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies","volume":"37","author":"Chabannon","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0072","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","article-title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","volume":"9","author":"Pennings","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102939_bib0073","unstructured":"Agency EM Concept paper on the revision of Part IV Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products 2025."},{"key":"10.1016\/j.jcyt.2026.102939_bib0074","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cimb47050321","article-title":"The Potential Use of Digital Twin Technology for Advancing CAR-T Cell Therapy","volume":"47","author":"Aghamiri","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102939_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.70045","article-title":"A digital shadow of CAR T cell expansion in a perfusion bioreactor: Informing optimal harvest times for autologous cell therapy","volume":"41","author":"Egan","year":"2025","journal-title":"Biotechnol Prog"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102939_bib0077","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40264-025-01596-9","article-title":"Pharmacovigilance in cell and gene therapy: evolving challenges in risk management and long-term follow-up","volume":"49","author":"Youssef","year":"2026","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcyt.2026.102939_bib0078","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102939_bib0079","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102939_bib0080","doi-asserted-by":"crossref","first-page":"200889","DOI":"10.1016\/j.omton.2024.200889","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand","volume":"32","author":"Luanpitpong","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2026.102939_bib0081","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600900X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532492600900X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:23:59Z","timestamp":1794572639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532492600900X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S146532492600900X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102939","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102939"}}